Despite a negative recommendation from the Oncologic Drugs Advisory Committee, Genentech Inc.'s Avastin (bevacizumab) gained accelerated approval from the FDA for use in combination with paclitaxel chemotherapy for the first-line treatment of metastatic HER2-negative breast cancer. (BioWorld Today)

Building a better obesity drug is no easy task. Obesity involves a host of genetic, behavioral, emotional and socio-cultural factors. And any successful drug will be taken by millions of patients, resulting in a safety hurdle that will "probably be greater than for any other drug out there," Kasimov said. (BioWorld Financial Watch)

Building a better obesity drug is no easy task. Obesity involves a host of genetic, behavioral, emotional and socio-cultural factors. And any successful drug will be taken by millions of patients, resulting in a safety hurdle that will "probably be greater than for any other drug out there," Kasimov said. (BioWorld Financial Watch)